(NYSE:NVO) Denmark on Friday cut its annual growth forecast to 1.4% from 3%.
Related Questions
How does Novo Nordisk's slowdown compare with its pharmaceutical peers and broader industry trends?
How will Denmark's reduced 2025 growth forecast affect Novo Nordisk's earnings outlook and valuation?
What immediate price reaction can be expected for NVO, and are there any short‑term trading setups?